Compare HELP & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELP | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | United States |
| Employees | 50 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.0M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | HELP | CDXS |
|---|---|---|
| Price | $5.03 | $2.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $51.50 | N/A |
| AVG Volume (30 Days) | 547.2K | ★ 756.7K |
| Earning Date | 07-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $3.76 | $0.96 |
| 52 Week High | $8.55 | $3.87 |
| Indicator | HELP | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 40.72 |
| Support Level | $4.86 | $1.57 |
| Resistance Level | $6.26 | $2.71 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 77.34 | 1.61 |
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.